Search Results - "Yang, James Chih Hsin"

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS) by FUKUOKA, Masahiro, WU, Yi-Long, DUFFIELD, Emma L, RUKAZENKOV, Yuri, SPEAKE, Georgina, HAIYI JIANG, ARMOUR, Alison A, TO, Ka-Fai, CHIH-HSIN YANG, James, MOK, Tony S. K, THONGPRASERT, Sumitra, SUNPAWERAVONG, Patrapim, LEONG, Swan-Swan, SRIURANPONG, Virote, CHAO, Tsu-Yi, NAKAGAWA, Kazuhiko, CHU, Da-Tong, SAIJO, Nagahiro

“…The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and carboplatin/paclitaxel in previously untreated never-smokers and light…”
Get full text

Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer by Su, Kang-Yi, Chen, Hsuan-Yu, Li, Ker-Chau, Kuo, Min-Liang, Yang, James Chih-Hsin, Chan, Wing-Kai, Ho, Bing-Ching, Chang, Gee-Chen, Shih, Jin-Yuan, Yu, Sung-Liang, Yang, Pan-Chyr

“…Patients with non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations have excellent response to EGFR tyrosine…”
Get full text

Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patients with activating EGFR mutations by Lin, Yen‐Ting, Chen, Jin‐Shing, Liao, Wei‐Yu, Ho, Chao‐Chi, Hsu, Chia‐Lin, Yang, Ching‐Yao, Chen, Kuan‐Yu, Lee, Jih‐Hsiang, Lin, Zhong‐Zhe, Shih, Jin‐Yuan, Yang, James Chih‐Hsin, Yu, Chong‐Jen

“…Gefitinib, erlotinib and afatinib are approved for first‐line treatment of advanced non‐small cell lung cancer (NSCLC) bearing an activating epidermal growth…”
Get full text

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib by Vishwanathan, Karthick, Dickinson, Paul A., So, Karen, Thomas, Karen, Chen, Yuh‐Min, De Castro Carpeño, Javier, Dingemans, Anne‐Marie C., Kim, Hye Ryun, Kim, Joo‐Hang, Krebs, Matthew G., Chih‐Hsin Yang, James, Bui, Khanh, Weilert, Doris, Harvey, R. Donald

“…Aims We investigated the effects of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampicin) on the pharmacokinetics of the epidermal growth factor…”
Get full text

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer by Yun, Mi Ran, Choi, Hun Mi, Lee, You Won, Joo, Hyeong Seok, Park, Chae Won, Choi, Jae Woo, Kim, Dong Hwi, Kang, Han Na, Pyo, Kyoung‐Ho, Shin, Eun Joo, Shim, Hyo Sup, Soo, Ross A, Yang, James Chih‐Hsin, Lee, Sung Sook, Chang, Hyun, Kim, Min Hwan, Hong, Min Hee, Kim, Hye Ryun, Cho, Byoung Chul

“…Clinical benefit of ALK tyrosine kinase inhibitors (ALK‐TKIs) in ALK ‐rearranged lung cancer has been limited by the inevitable development of acquired…”
Get full text

Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis by Lee, Chee Khoon, Man, Johnathan, Lord, Sally, Links, Matthew, Gebski, Val, Mok, Tony, Yang, James Chih-Hsin

“…We performed a meta-analysis to assess the role of immune checkpoint inhibitors as second-line therapy in EGFR-mutant advanced NSCLC. Randomized trials…”
Get more information

Real‐World Data on Prognostic Factors for Overall Survival in EGFR Mutation‐Positive Advanced Non‐Small Cell Lung Cancer Patients Treated with First‐Line Gefitinib by Yao, Zong‐Han, Liao, Wei‐Yu, Ho, Chao‐Chi, Chen, Kuan‐Yu, Shih, Jin‐Yuan, Chen, Jin‐Shing, Lin, Zhong‐Zhe, Lin, Chia‐Chi, Chih‐Hsin Yang, James, Yu, Chong‐Jen

“…Background This study aimed to identify independent prognostic factors for overall survival (OS) of patients with advanced non‐small cell lung cancer (NSCLC)…”
Get full text

Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion by Wu, Shang‐Gin, Liu, Yi‐Nan, Yu, Chong‐Jen, Yang, James Chih‐Hsin, Shih, Jin‐Yuan

“…Young lung cancer patients have several distinct characteristics. However, there are limited epidemiological data of genetic abnormalities in this population…”
Get full text

Clinical Outcomes in Non―Small Cell Lung Cancers Harboring Different Exon 19 Deletions in EGFR by CHUNG, Kuei-Pin, WU, Shang-Gin, WU, Jenn-Yu, CHIH-HSIN YANG, James, YU, Chong-Jen, WEI, Pin-Fei, SHIH, Jin-Yuan, YANG, Pan-Chyr

“…Several deletions in exon 19 of epidermal growth factor receptor (EGFR) gene have been reported in non-small cell lung cancer (NSCLC). It is unknown if…”
Get full text

Precision Management of Advanced Non-Small Cell Lung Cancer by Yang, Ching-Yao, Yang, James Chih-Hsin, Yang, Pan-Chyr

“…The rapid evolution of treatment for advanced lung cancer is a story of how scientists have struggled to move from nonselective cytotoxic chemotherapy to…”
Get full text

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases by Yang, James Chih-Hsin, Schuler, Martin, Popat, Sanjay, Miura, Satoru, Heeke, Simon, Park, Keunchil, Märten, Angela, Kim, Edward S

“…Limited clinical data are available regarding the efficacy of EGFR tyrosine kinase inhibitors (EGFR TKIs) in patients with NSCLC harboring uncommon EGFR…”
Get more information

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study by Rudin, Charles M, Awad, Mark M, Navarro, Alejandro, Gottfried, Maya, Peters, Solange, Csőszi, Tibor, Cheema, Parneet K, Rodriguez-Abreu, Delvys, Wollner, Mirjana, Yang, James Chih-Hsin, Mazieres, Julien, Orlandi, Francisco J, Luft, Alexander, Gümüş, Mahmut, Kato, Terufumi, Kalemkerian, Gregory P, Luo, Yiwen, Ebiana, Victoria, Pietanza, M Catherine, Kim, Hye Ryun

“…Pembrolizumab monotherapy has shown antitumor activity in patients with small-cell lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604…”
Get full text

Clinical activity of ASP8273 in Asian patients with non‐small‐cell lung cancer with EGFR activating and T790M mutations by Murakami, Haruyasu, Nokihara, Hiroshi, Hayashi, Hidetoshi, Seto, Takashi, Park, Keunchil, Azuma, Koichi, Tsai, Chun‐Ming, Yang, James Chih‐Hsin, Nishio, Makoto, Kim, Sang‐We, Kiura, Katsuyuki, Inoue, Akira, Takeda, Koji, Kang, Jin‐Hyoung, Nakagawa, Tomoki, Takeda, Kentaro, Akazawa, Rio, Kaneko, Yuichiro, Shimazaki, Masashi, Morita, Satoshi, Fukuoka, Masahiro, Nakagawa, Kazuhiko

“…Epidermal growth factor receptor (EGFR)‐activating mutations confer sensitivity to tyrosine kinase inhibitor (TKI) treatment for non‐small‐cell lung cancer…”
Get full text

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations by SEQUIST, Lecia V, YANG, James Chih-Hsin, SU, Wu-Chou, BENNOUNA, Jaafar, KATO, Terufumi, GORBUNOVA, Vera, KI HYEONG LEE, SHAH, Riyaz, MASSEY, Dan, ZAZULINA, Victoria, SHAHIDI, Mehdi, SCHULER, Martin, YAMAMOTO, Nobuyuki, O'BYRNE, Kenneth, HIRSH, Vera, MOK, Tony, GEATER, Sarayut Lucien, ORLOV, Sergey, TSAI, Chun-Ming, BOYER, Michael

“…The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly…”
Get full text

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer by Jänne, Pasi A, Yang, James Chih-Hsin, Kim, Dong-Wan, Planchard, David, Ohe, Yuichiro, Ramalingam, Suresh S, Ahn, Myung-Ju, Kim, Sang-We, Su, Wu-Chou, Horn, Leora, Haggstrom, Daniel, Felip, Enriqueta, Kim, Joo-Hang, Frewer, Paul, Cantarini, Mireille, Brown, Kathryn H, Dickinson, Paul A, Ghiorghiu, Serban, Ranson, Malcolm

“…AZD9291, an irreversible inhibitor of epidermal growth factor receptor, was associated with tumor responses in the majority of patients with advanced…”
Get full text

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component by Yang, James Chih-Hsin, Ahn, Myung-Ju, Kim, Dong-Wan, Ramalingam, Suresh S, Sequist, Lecia V, Su, Wu-Chou, Kim, Sang-We, Kim, Joo-Hang, Planchard, David, Felip, Enriqueta, Blackhall, Fiona, Haggstrom, Daniel, Yoh, Kiyotaka, Novello, Silvia, Gold, Kathryn, Hirashima, Tomonori, Lin, Chia-Chi, Mann, Helen, Cantarini, Mireille, Ghiorghiu, Serban, Jänne, Pasi A

“…Purpose Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) selective for both EGFR-TKI sensitizing ( EGFRm)…”
Get full text

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study by Langer, Corey J, Dr Prof, Gadgeel, Shirish M, Prof, Borghaei, Hossein, DO, Papadimitrakopoulou, Vassiliki A, Prof, Patnaik, Amita, MD, Powell, Steven F, MD, Gentzler, Ryan D, MD, Martins, Renato G, Prof, Stevenson, James P, MD, Jalal, Shadia I, MBBS, Panwalkar, Amit, MD, Yang, James Chih-Hsin, Prof, Gubens, Matthew, MD, Sequist, Lecia V, MD, Awad, Mark M, MD, Fiore, Joseph, PharmD, Ge, Yang, PhD, Raftopoulos, Harry, MD, Gandhi, Leena, Prof

“…Summary Background Limited evidence exists to show that adding a third agent to platinum-doublet chemotherapy improves efficacy in the first-line advanced…”
Get full text

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study by Ou, Sai-Hong Ignatius, Ahn, Jin Seok, De Petris, Luigi, Govindan, Ramaswamy, Yang, James Chih-Hsin, Hughes, Brett, Lena, Hervé, Moro-Sibilot, Denis, Bearz, Alessandra, Ramirez, Santiago Viteri, Mekhail, Tarek, Spira, Alexander, Bordogna, Walter, Balas, Bogdana, Morcos, Peter N, Monnet, Annabelle, Zeaiter, Ali, Kim, Dong-Wan

“…Crizotinib confers improved progression-free survival compared with chemotherapy in anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer…”
Get full text

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial by Park, Keunchil, Prof, Tan, Eng-Huat, MD, O'Byrne, Ken, Prof, Zhang, Li, Prof, Boyer, Michael, Prof, Mok, Tony, Prof, Hirsh, Vera, Prof, Yang, James Chih-Hsin, Prof, Lee, Ki Hyeong, MD, Lu, Shun, Prof, Shi, Yuankai, MD, Kim, Sang-We, MD, Laskin, Janessa, MD, Kim, Dong-Wan, Prof, Arvis, Catherine Dubos, MD, Kölbeck, Karl, MD, Laurie, Scott A, MD, Tsai, Chun-Ming, Prof, Shahidi, Mehdi, MD, Kim, Miyoung, MD, Massey, Dan, PhD, Zazulina, Victoria, MD, Paz-Ares, Luis, MD

“…Summary Background The irreversible ErbB family blocker afatinib and the reversible EGFR tyrosine kinase inhibitor gefitinib are approved for first-line…”
Get full text

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR -Mutated Non-Small Cell Lung Cancer by Jänne, Pasi A, Baik, Christina, Su, Wu-Chou, Johnson, Melissa L, Hayashi, Hidetoshi, Nishio, Makoto, Kim, Dong-Wan, Koczywas, Marianna, Gold, Kathryn A, Steuer, Conor E, Murakami, Haruyasu, Yang, James Chih-Hsin, Kim, Sang-We, Vigliotti, Michele, Shi, Rong, Qi, Zhenhao, Qiu, Yang, Zhao, Lihui, Sternberg, David, Yu, Channing, Yu, Helena A

“…Receptor tyrosine-protein kinase ERBB3 (HER3) is expressed in most -mutated lung cancers but is not a known mechanism of resistance to EGFR inhibitors…”
Get more information